Authors
Weihui Guo, Yuxin Weng, Fang Wu, Lei Wang, Zhenyuan Qian, Zaiyuan Ye, Guangyuan Song, Ji Xu
Published in
International journal of biological macromolecules. Pages 153878. Aug 01, 2026. Epub Aug 01, 2026.
Abstract
Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related deaths, with limited therapeutic options. Ferroptosis, an iron-dependent form of cell death characterized by lipid peroxidation, has emerged as a promising approach for HCC intervention due to its close association with multiple aspects of liver cancer, such as proliferation, metastasis, and drug resistance. In this study, we identified the oncogene mitochondrial ribosomal protein S30 (MRPS30) associated with HCC prognosis through multi-omics analysis. Using HCC cell lines with MRPS30 knockdown/overexpression and xenograft tumor models, we confirmed that MRPS30 inhibits ferroptosis by upregulating Glutathione Peroxidase 4(GPX4), thereby promoting the malignant progression of HCC and resistance to lenvatinib. Mechanistically, MRPS30 specifically interacts with GPX4 and inhibits the lysine 48 (K48)-linked ubiquitination of GPX4 to maintain its protein stability. By stabilizing GPX4, MRPS30 reduces malondialdehyde (MDA) accumulation and maintains glutathione (GSH) homeostasis, thereby inhibiting ferroptosis and ultimately enhancing the malignant behaviors and drug resistance of HCC. In conclusion, we identified MRPS30 as a prognosis-related gene in HCC and revealed its role in regulating HCC proliferation, metastasis, and drug resistance through ferroptosis. Our findings uncover a key driver of ferroptosis resistance mediated by the MRPS30/GPX4 axis and further confirm that ferroptosis is a promising therapeutic strategy for HCC treatment.
PMID:
42542152
Bibliographic data and abstract were imported from PubMed on 02 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0